Developer docs
API playgroundTry for free, no card

Search company profiles

Monteris Medical

Full company profile

uuid0000jp6

Namestring
Monteris Medical
Legal namestring
Monteris Medical Corporation
Websiteurl
monteris.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Monteris Medical is a privately held medical device company founded in 1999 that develops and commercializes the NeuroBlate System, the only robotic MR-guided laser interstitial thermal therapy (LITT) platform designed specifically for use in the brain. Headquartered in Minnetonka, Minnesota with a Canadian office in Winnipeg, Manitoba, the company targets neurosurgeons and hospitals/health systems for the minimally invasive treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. The platform addresses the need for alternatives to open craniotomy, particularly for deep-seated lesions, recurrent tumors, fragile patients, and drug-resistant epilepsy patients who have failed more than two medication regimens.

The NeuroBlate System is an integrated platform comprising capital equipment (robotic MR-guided ablation workstation), consumable laser probes (FullFire, SideFire, and the NB3 1.6mm — the smallest commercially available brain laser probe), Fusion-S 3D visualization and control software, the AtamA patient board, and the MiniBolt cranial bolt system. The system uses proprietary cooled laser probe technology that enables ablation of lesions 3 cm or larger in diameter while preserving surrounding healthy tissue, and is differentiated by remote robotic control that allows the surgeon to direct probe positioning from a workstation rather than from inside the MR scan room. Multiple U.S. and international patents cover the system, probes, probe driver, patient board, and AXiiiS stereotactic miniframe.

Monteris generates revenue primarily through direct enterprise sales of capital equipment and per-procedure consumables to hospitals and health systems, supplemented by clinical trial and research support. The company sells through a dedicated North American sales organization (including a VP of North American Sales) into nearly 130 health systems across the U.S. and Canada, with the system used in over 9,000 cumulative clinical cases. Reimbursement has been secured with Medicare, leading commercial insurers, and — as of January 2026 — TRICARE, expanding access to over 9 million U.S. military members and their families. The company has raised approximately $200 million in total capital across multiple equity and debt rounds, with the CEO publicly targeting $100 million in sales, and supports prospective multicenter clinical research including the LAANTERN registry (1,000+ patients) and the REMASTer randomized trial.

Short descriptiontext

Monteris Medical is a private medical device company that develops the NeuroBlate System, a robotic MR-guided LITT platform for minimally invasive brain surgery. It sells capital equipment and consumables to hospitals and neurosurgeons treating brain tumors, radiation necrosis, and drug-resistant epilepsy across North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMinnetonka, United States
HQ citystring
Minnetonka
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
MRI-guided laser ablation, minimally invasive neurosurgery, laser interstitial thermal therapy, neurosurgical medical devices, brain tumor ablation devices
Industry3 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Minimally Invasive Neurosurgical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1NeuroBlate System Capital Equipment Sales
TypeHardware Sales
Description

Monteris sells its NeuroBlate System as capital medical equipment to hospitals and health systems. The system includes the main platform, robotic components, and software. Additionally, the company generates revenue from compatible accessories and consumables including laser probes (FullFire, SideFire, NB3) and Mini-Bolt cranial bolts.

monteris.com
2Clinical Trial and Research Support
TypeProfessional Services
Description

Monteris supports investigator-initiated research allowing partnership with investigators in LITT early phase research. The company also conducts post-market and randomized multicenter clinical trials including LAANTERN study with over 1,000 patients enrolled.

monteris.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NeuroBlate System
Description

MR-guided laser ablation platform for minimally invasive neurosurgery, used for brain tumors, radiation necrosis, and drug-resistant epilepsy.

monteris.com
+2 more records
Core offering1 text field

Monteris Medical develops and sells the NeuroBlate System, the only robotic MR-guided laser ablation platform specifically designed for minimally invasive brain surgery. The system delivers laser interstitial thermal therapy (LITT) for treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. Revenue is generated through capital equipment sales to hospitals, alongside recurring consumables revenue from laser probes (FullFire, SideFire, NB3) and cranial bolt accessories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Seizure freedom (Engel I) achieved in 64.3% of drug-resistant epilepsy patients at 1 year per LAANTERN study
+6 more records
Product overview1 text field

Monteris Medical offers a unified medical device platform centered on the NeuroBlate System, the only robotic MR-guided laser ablation technology specifically designed for brain surgery. The system comprises the NeuroBlate capital platform with robotic probe drivers, multiple laser probe options (FullFire and SideFire in various sizes including the NB3 1.6mm), Fusion-S visualization software, and supporting accessories (AtamA patient board, MiniBolt cranial bolts). The NeuroBlate System delivers MRI-guided laser interstitial thermal therapy (LITT) for ablation of brain tumors, radiation necrosis, and drug-resistant epilepsy. Clinical support is provided through prospective multicenter studies including the LAANTERN registry and REMASTer randomized trial, with the system used in nearly 130 health systems across North America.

Product and service7 records
1NeuroBlate System
CategoryNeurosurgical capital equipment
Description

The only robotic MR-guided laser ablation platform specifically designed for minimally invasive brain surgery, enabling precise destruction of abnormal brain tissue including brain tumors, radiation necrosis, and epileptic foci through laser interstitial thermal therapy (LITT). Sold to hospitals and health systems.

2NeuroBlate NB3 FullFire 1.6mm Laser Probe
CategoryNeurosurgical consumables / laser probes
Description

The smallest commercially available laser probe (1.6mm) for brain lesion ablations, featuring patented cooled laser probe technology for optimized heat propagation and ablation control across various lesion sizes. Consumable used with the NeuroBlate System.

3NeuroBlate FullFire Laser Probe
CategoryNeurosurgical consumables / laser probes
Description

Diffuse-tip laser probe providing versatility for tailoring the approach to each unique lesion. Available in 1.6mm and 3.3mm sizes. Consumable used with the NeuroBlate System.

4NeuroBlate SideFire Laser Probe
CategoryNeurosurgical consumables / laser probes
Description

Directional laser probe offering surgeons versatility to tailor approach for each unique lesion, complementing the FullFire diffuse probe. Consumable used with the NeuroBlate System.

5NeuroBlate Fusion-S Software
CategoryNeurosurgical software / visualization platform
Description

MRI-guided visualization, control, and efficiency software for brain tissue laser ablation, with 3D volumetric visualization, multi-slice thermal views, a 4–12W power range, unlimited temperature pick points, and built-in safety tools including thermal dose threshold lines and auto-stop options. Software component of the NeuroBlate System.

6AtamA Patient Board System
CategoryNeurosurgical accessories / patient positioning
Description

Patient positioning device used in conjunction with the NeuroBlate System to apply focused laser energy while protecting surrounding healthy tissue during MRI-guided brain ablation procedures. Accessory for the NeuroBlate System.

7MiniBolt Cranial Bolt System and Accessories
CategoryNeurosurgical accessories / cranial access
Description

Cranial bolt system designed to work with NeuroBlate robotics to reduce MRI profile and provide access to virtually any brain location for laser probe insertion. Accessory for the NeuroBlate System.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-09
Description

Strategic partnership to develop AI-powered micro-robotic platform for brain laser ablation. Combines Symphony's MRI-guided, magnetically actuated micro-robotic arm with Monteris' NeuroBlate LITT system. Partnership aims to enable more precise, micro-invasive surgeries through non-linear trajectories in the brain for treating brain tumors and drug-resistant epilepsy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major neurosurgery navigation and planning software vendor with broad cranial and spinal platforms. Competes with Monteris for neurosurgical workflow mindshare and increasingly offers image-guided therapy tools that overlap with NeuroBlate's positioning.

TypeBroad incumbent
Description

Manufactures the CyberKnife robotic radiosurgery system, which is a competing modality for many brain tumor and radiation necrosis cases that NeuroBlate also addresses. Often positioned as an alternative rather than complement to LITT.

TypeEmerging player
Description

UK-based manufacturer of the neuromate stereotactic robotic system for neurosurgery. Smaller and more niche than Monteris but offers robotic stereotactic placement for DBS and ablation procedures, competing for neurosurgery robotics budgets.

TypeBroad incumbent
Description

Neurovascular device company with a growing footprint in neurosurgery through stroke thrombectomy and more recently brain tumor access tools. Could emerge as a competitor in minimally invasive neurosurgical procedures adjacent to LITT.

TypeDirect peer
Description

Provides MRI-guided neurosurgical navigation and drug delivery platforms used in conjunction with LITT procedures. ClearPoint's cannulas and navigation system are often used alongside NeuroBlate, making it both a partner and a competitor in the MRI-guided neurosurgery workflow.

TypeBroad incumbent
Description

Through its ROSA robotic platform, Zimmer Biomet offers surgical robotics for neurosurgical and orthopedic procedures. While primarily orthopedic-focused, ROSA represents a competing robotic neurosurgery platform for hospitals standardizing their OR robotics.

TypeBroad incumbent
Description

Broad neurosurgery portfolio including cranial closure, dural repair, and image-guided surgery products. Competes for hospital neurosurgery budget and shelf space and offers overlapping cranial access accessories used in LITT workflows.

TypeBroad incumbent
Description

Through its acquired Navigation business (formerly Stryker Leibinger), offers cranial navigation systems used in neurosurgical operating rooms. The VP of Sales at Monteris previously held roles at Stryker Navigation, underscoring the close competitive overlap.

TypeDirect peer
Description

Acquired Visualase in 2014, the other commercially available MR-guided laser interstitial thermal therapy system for brain surgery. Visualase is the closest direct competitor to Monteris' NeuroBlate, both targeting brain tumors and epilepsy with MRI-guided laser ablation.

TypeBroad incumbent
Description

Maker of Leksell Gamma Knife and linear accelerators used for stereotactic radiosurgery of brain tumors and functional disorders including epilepsy. Represents the dominant alternative modality for many indications NeuroBlate targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Monteris Medical

Minimally Invasive Neurosurgical Devicesmonteris.com

Monteris Medical is a private medical device company that develops the NeuroBlate System, a robotic MR-guided LITT platform for minimally invasive brain surgery. It sells capital equipment and consumables to hospitals and neurosurgeons treating brain tumors, radiation necrosis, and drug-resistant epilepsy across North America.

What Monteris Medical does

Monteris Medical is a privately held medical device company founded in 1999 that develops and commercializes the NeuroBlate System, the only robotic MR-guided laser interstitial thermal therapy (LITT) platform designed specifically for use in the brain. Headquartered in Minnetonka, Minnesota with a Canadian office in Winnipeg, Manitoba, the company targets neurosurgeons and hospitals/health systems for the minimally invasive treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. The platform addresses the need for alternatives to open craniotomy, particularly for deep-seated lesions, recurrent tumors, fragile patients, and drug-resistant epilepsy patients who have failed more than two medication regimens.

The NeuroBlate System is an integrated platform comprising capital equipment (robotic MR-guided ablation workstation), consumable laser probes (FullFire, SideFire, and the NB3 1.6mm — the smallest commercially available brain laser probe), Fusion-S 3D visualization and control software, the AtamA patient board, and the MiniBolt cranial bolt system. The system uses proprietary cooled laser probe technology that enables ablation of lesions 3 cm or larger in diameter while preserving surrounding healthy tissue, and is differentiated by remote robotic control that allows the surgeon to direct probe positioning from a workstation rather than from inside the MR scan room. Multiple U.S. and international patents cover the system, probes, probe driver, patient board, and AXiiiS stereotactic miniframe.

Monteris generates revenue primarily through direct enterprise sales of capital equipment and per-procedure consumables to hospitals and health systems, supplemented by clinical trial and research support. The company sells through a dedicated North American sales organization (including a VP of North American Sales) into nearly 130 health systems across the U.S. and Canada, with the system used in over 9,000 cumulative clinical cases. Reimbursement has been secured with Medicare, leading commercial insurers, and — as of January 2026 — TRICARE, expanding access to over 9 million U.S. military members and their families. The company has raised approximately $200 million in total capital across multiple equity and debt rounds, with the CEO publicly targeting $100 million in sales, and supports prospective multicenter clinical research including the LAANTERN registry (1,000+ patients) and the REMASTer randomized trial.

Monteris Medical firmographics

Firmographics
Name
Monteris Medical
Legal name
Monteris Medical Corporation
Website
https://monteris.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Monteris Medical is a private medical device company that develops the NeuroBlate System, a robotic MR-guided LITT platform for minimally invasive brain surgery. It sells capital equipment and consumables to hospitals and neurosurgeons treating brain tumors, radiation necrosis, and drug-resistant epilepsy across North America.
Ownership category
akta.pro rank

Monteris Medical industry classification

Industry
Product category
Minimally Invasive Neurosurgical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAG
Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • MRI-guided laser ablation
  • Minimally invasive neurosurgery
  • Laser interstitial thermal therapy
  • Neurosurgical medical devices
  • Brain tumor ablation devices

Where Monteris Medical is headquartered

Location

Headquarters

HQ city
Minnetonka
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Monteris Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. NeuroBlate System Capital Equipment Sales: Monteris sells its NeuroBlate System as capital medical equipment to hospitals and health systems. The system includes the main platform, robotic components, and software. Additionally, the company generates revenue from compatible accessories and consumables including laser probes (FullFire, SideFire, NB3) and Mini-Bolt cranial bolts.
  2. Clinical Trial and Research Support: Monteris supports investigator-initiated research allowing partnership with investigators in LITT early phase research. The company also conducts post-market and randomized multicenter clinical trials including LAANTERN study with over 1,000 patients enrolled.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Monteris Medical product offering

Product offering

Core offering

Monteris Medical develops and sells the NeuroBlate System, the only robotic MR-guided laser ablation platform specifically designed for minimally invasive brain surgery. The system delivers laser interstitial thermal therapy (LITT) for treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. Revenue is generated through capital equipment sales to hospitals, alongside recurring consumables revenue from laser probes (FullFire, SideFire, NB3) and cranial bolt accessories.

Product overview

Monteris Medical offers a unified medical device platform centered on the NeuroBlate System, the only robotic MR-guided laser ablation technology specifically designed for brain surgery. The system comprises the NeuroBlate capital platform with robotic probe drivers, multiple laser probe options (FullFire and SideFire in various sizes including the NB3 1.6mm), Fusion-S visualization software, and supporting accessories (AtamA patient board, MiniBolt cranial bolts). The NeuroBlate System delivers MRI-guided laser interstitial thermal therapy (LITT) for ablation of brain tumors, radiation necrosis, and drug-resistant epilepsy. Clinical support is provided through prospective multicenter studies including the LAANTERN registry and REMASTer randomized trial, with the system used in nearly 130 health systems across North America.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroBlate System: MR-guided laser ablation platform for minimally invasive neurosurgery, used for brain tumors, radiation necrosis, and drug-resistant epilepsy.
  • AtamA System
  • Mini-Bolt

Products and services

  • NeuroBlate System The only robotic MR-guided laser ablation platform specifically designed for minimally invasive brain surgery, enabling precise destruction of abnormal brain tissue including brain tumors, radiation necrosis, and epileptic foci through laser interstitial thermal therapy (LITT). Sold to hospitals and health systems.
  • NeuroBlate NB3 FullFire 1.6mm Laser Probe The smallest commercially available laser probe (1.6mm) for brain lesion ablations, featuring patented cooled laser probe technology for optimized heat propagation and ablation control across various lesion sizes. Consumable used with the NeuroBlate System.
  • NeuroBlate FullFire Laser Probe Diffuse-tip laser probe providing versatility for tailoring the approach to each unique lesion. Available in 1.6mm and 3.3mm sizes. Consumable used with the NeuroBlate System.
  • NeuroBlate SideFire Laser Probe Directional laser probe offering surgeons versatility to tailor approach for each unique lesion, complementing the FullFire diffuse probe. Consumable used with the NeuroBlate System.
  • NeuroBlate Fusion-S Software MRI-guided visualization, control, and efficiency software for brain tissue laser ablation, with 3D volumetric visualization, multi-slice thermal views, a 4–12W power range, unlimited temperature pick points, and built-in safety tools including thermal dose threshold lines and auto-stop options. Software component of the NeuroBlate System.
  • AtamA Patient Board System Patient positioning device used in conjunction with the NeuroBlate System to apply focused laser energy while protecting surrounding healthy tissue during MRI-guided brain ablation procedures. Accessory for the NeuroBlate System.
  • MiniBolt Cranial Bolt System and Accessories Cranial bolt system designed to work with NeuroBlate robotics to reduce MRI profile and provide access to virtually any brain location for laser probe insertion. Accessory for the NeuroBlate System.

Quantifiable outcome

  • Seizure freedom (Engel I) achieved in 64.3% of drug-resistant epilepsy patients at 1 year per LAANTERN study
  • +6 more outcomes

Companies that use Monteris Medical

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Monteris Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Monteris Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Symphony RoboticscoreTechnology or Integration · 9 October 2025Strategic partnership to develop AI-powered micro-robotic platform for brain laser ablation. Combines Symphony's MRI-guided, magnetically actuated micro-robotic arm with Monteris' NeuroBlate LITT system. Partnership aims to enable more precise, micro-invasive surgeries through non-linear trajectories in the brain for treating brain tumors and drug-resistant epilepsy.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Monteris Medical competitors and assessment

Company assessment

Broad incumbents

  • Brainlab: Major neurosurgery navigation and planning software vendor with broad cranial and spinal platforms. Competes with Monteris for neurosurgical workflow mindshare and increasingly offers image-guided therapy tools that overlap with NeuroBlate's positioning.
  • Accuray (CyberKnife): Manufactures the CyberKnife robotic radiosurgery system, which is a competing modality for many brain tumor and radiation necrosis cases that NeuroBlate also addresses. Often positioned as an alternative rather than complement to LITT.
  • Penumbra: Neurovascular device company with a growing footprint in neurosurgery through stroke thrombectomy and more recently brain tumor access tools. Could emerge as a competitor in minimally invasive neurosurgical procedures adjacent to LITT.
  • Zimmer Biomet (ROSA): Through its ROSA robotic platform, Zimmer Biomet offers surgical robotics for neurosurgical and orthopedic procedures. While primarily orthopedic-focused, ROSA represents a competing robotic neurosurgery platform for hospitals standardizing their OR robotics.
  • Integra LifeSciences: Broad neurosurgery portfolio including cranial closure, dural repair, and image-guided surgery products. Competes for hospital neurosurgery budget and shelf space and offers overlapping cranial access accessories used in LITT workflows.
  • Stryker (Navigation): Through its acquired Navigation business (formerly Stryker Leibinger), offers cranial navigation systems used in neurosurgical operating rooms. The VP of Sales at Monteris previously held roles at Stryker Navigation, underscoring the close competitive overlap.
  • Elekta (Leksell Gamma Knife): Maker of Leksell Gamma Knife and linear accelerators used for stereotactic radiosurgery of brain tumors and functional disorders including epilepsy. Represents the dominant alternative modality for many indications NeuroBlate targets.

Emerging players

  • Renishaw (neuromate): UK-based manufacturer of the neuromate stereotactic robotic system for neurosurgery. Smaller and more niche than Monteris but offers robotic stereotactic placement for DBS and ablation procedures, competing for neurosurgery robotics budgets.

Direct peers

  • ClearPoint Neuro: Provides MRI-guided neurosurgical navigation and drug delivery platforms used in conjunction with LITT procedures. ClearPoint's cannulas and navigation system are often used alongside NeuroBlate, making it both a partner and a competitor in the MRI-guided neurosurgery workflow.
  • Medtronic (Visualase): Acquired Visualase in 2014, the other commercially available MR-guided laser interstitial thermal therapy system for brain surgery. Visualase is the closest direct competitor to Monteris' NeuroBlate, both targeting brain tumors and epilepsy with MRI-guided laser ablation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Monteris Medical social profiles

Digital presence

Monteris Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Monteris Medical leadership team

Management profile

Number of profiles

Profiles9 records

Monteris Medical funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Monteris Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monteris Medical

What does Monteris Medical do?

Monteris Medical develops and sells the NeuroBlate System, the only robotic MR-guided laser ablation platform specifically designed for minimally invasive brain surgery. The system delivers laser interstitial thermal therapy (LITT) for treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. Revenue is generated through capital equipment sales to hospitals, alongside recurring consumables revenue from laser probes (FullFire, SideFire, NB3) and cranial bolt accessories.

Is Monteris Medical a public or private company?

Monteris Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Monteris Medical founded?

Monteris Medical was founded in 1999. It employs 101 to 250 people.

Where is Monteris Medical based?

Monteris Medical is headquartered in Minnetonka, United States, in the North America region.

How does Monteris Medical make money?

Two revenue lines are on record. NeuroBlate System Capital Equipment Sales are the primary driver. The others are clinical Trial and Research Support.

Who are Monteris Medical's main competitors?

Broad incumbents on record are Brainlab, Accuray (CyberKnife), Penumbra, Zimmer Biomet (ROSA), Integra LifeSciences, Stryker (Navigation) and Elekta (Leksell Gamma Knife). Renishaw (neuromate) is listed as an emerging player. Direct peers are ClearPoint Neuro and Medtronic (Visualase).

Does Monteris Medical have an API?

No public API is recorded for Monteris Medical.

What industry is Monteris Medical in?

Monteris Medical's product category is Minimally Invasive Neurosurgical Devices. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMonteris Medical Announces Publication of Landmark Study on 787 Brain Tumor Patients Treated with NeuroBlate® Laser Interstitial Thermal Therapy (LITT)Monteris Medical announced the publication of a study in the Journal of Clinical Oncology analyzing outcomes from 787 patients treated with its NeuroBlate System. The research identified that achieving at least 91% tumor ablation is a critical determinant for improved survival rates in glioblastoma and metastatic brain tumors. The findings reinforce the clinical value of minimally invasive laser interstitial thermal therapy as a proactive treatment option.News-MedicalLaser treatment may extend survival in glioblastoma patientsA study led by Washington University School of Medicine published in the Journal of Clinical Oncology found that laser interstitial thermal therapy (LITT) can extend survival for glioblastoma patients, particularly when at least 91% of the tumor is removed. The analysis of 787 patients indicated that this minimally invasive procedure offers a survival advantage over standard open surgery and improves quality of life with shorter hospital stays. The technology used, NeuroBlate, was developed by Monteris Medical, which funded the research.Mirage NewsLaser Therapy Targets Deadly Brain TumorsResearchers at Washington University School of Medicine published an analysis in the Journal of Clinical Oncology identifying that extensive tumor removal and early timing significantly extend survival for patients undergoing laser interstitial thermal therapy (LITT) for brain tumors. The study, which analyzed 787 patients across the U.S., found that ablating at least 91% of glioblastoma tumors extended survival to 2.1 years compared to 1.5 years with standard surgery, while treating smaller metastases earlier also improved outcomes. The minimally invasive procedure utilizes the NeuroBlate surgical tool developed by Monteris Medical.American City Business JournalsMonteris Medical targets $100 million revenue with new fundingMonteris Medical raised more than $60 million in funding to expand sales of its robotic laser treatment for brain cancer and epilepsy. The Minnetonka-based medtech company states it has the infrastructure to hire additional staff and target $100 million in sales. The CEO cited the funding as enabling the company's growth trajectory toward its revenue goal.Winnipeg Free PressMonteris Medical wraps up US$28M in Series E funding roundMonteris Medical, a medical device company headquartered in Winnipeg, has closed a Series E funding round raising US$28 million. The investment will support the company's continued growth and development of its neurosurgical medical devices. This successful capital raise signals investor confidence in the company's technology and growth trajectory.openPR.comKey Strategic Trends and Emerging Changes Shaping the Micro Robots Market LandscapeThe Business Research Company published a market report projecting the micro robots market to reach $5.54 billion by 2030, growing at a 12.6% CAGR, driven by demand for targeted drug delivery, AI adoption, and precision manufacturing. In October 2025, Monteris Medical partnered with Symphony Robotics to develop an AI-powered micro-robotic platform for brain laser ablation to enhance neurosurgical procedures. In December 2025, the University of Pennsylvania and the University of Michigan unveiled the world's smallest fully programmable autonomous microrobots, measuring approximately 200 × 300 × 50 micrometers and produced at roughly one cent each.MassDeviceMonteris Medical raises $28M Series E for robotic neurosurgery techMonteris Medical, a Minnesota-based medical device company, has closed a $28 million Series E equity financing round to advance its robotic minimally invasive neurosurgery technology. The company also refinanced its current debt and established a new $35 million credit facility with Trinity Capital, bringing its total capital raised to approximately $200 million. The NeuroBlate system, the company's FDA-approved MRI-guided laser ablation platform, has now been used in over 9,000 clinical cases across nearly 130 health systems in North America.BioSpaceMonteris Medical Secures $28 Million in Growth Equity to Accelerate Revenue and Innovation in Minimally Invasive NeurosurgeryMonteris Medical closed $28 million in Series E equity financing to support technology innovation and expand its U.S. commercial footprint in minimally invasive neurosurgery. The company also refinanced its existing debt and secured a new $35 million credit facility with Trinity Capital, replacing its prior facility with Madryn Asset Management. The funding round included existing investors InnovaHealth Partners and Birchview Capital, along with new investors OSF Ventures and the Colorado University Healthcare Innovation Fund.Pulse 2.0Monteris Medical: $35 Million Debt Financing From Alternative Asset Manager To Expand Neurosurgical TechnologyTrinity Capital committed $35 million in growth capital to Monteris Medical, a MedTech firm developing the NeuroBlate System, a robotically controlled laser interstitial thermal therapy platform for brain tumors and epilepsy. The financing will support commercialization and clinical research, with the company aiming to expand adoption across neuroscience centers.Stock TitanTrinity Capital commits $35M to Monteris MedicalTrinity Capital Inc. announced a $35 million growth capital commitment to Monteris Medical, a MedTech company specializing in minimally invasive neurosurgical technology. The funding will support the commercialization of Monteris's NeuroBlate System, a robotically controlled MRI-guided laser therapy platform used to treat brain tumors, radiation necrosis, and drug-resistant epilepsy, as well as expansion of clinical research programs. The investment reflects Trinity Capital's confidence in Monteris's strategy and the expanding clinical impact of its technology across leading neuroscience centers.